CNS trauma biomarkers and surrogate endpoints pipeline from bench to bedside: A translational perspective

Brain Neurotrauma: Molecular, Neuropsychological, and Rehabilitation Aspects

Volumn , Issue , 2015, Pages 275-288

  Mouhieddine, Tarek H ^a   El Houjeiri, Leeanna ^a   Sabra, Mirna ^b   Hayes, Ronald L ^c   Mondello, Stefania ^d  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b LEBANESE UNIVERSITY   (Lebanon)

^c BANYAN BIOMARKERS INC   (United States)

^d UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85043592504     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b18126     Document Type: Chapter

References (152)

1. Acimovic, M., K. Dabic-Stankovic, T. Pejcic, Z. Dzamic, D. Rafailovic, and J. Hadzi-Djokic. 2013. Preoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy. Journal of B.U.ON.: Official journal of the Balkan Union of Oncology. 18:954-960.
2. Agoston, D.V., A. Gyorgy, O. Eidelman, and H.B. Pollard. 2009. Proteomic biomarkers for blast neurotrauma: Targeting cerebral edema, inflammation, and neuronal death cascades. J Neurotrauma. 26:901-911.
3. Ahmed, F., A. Gyorgy, A. Kamnaksh, G. Ling, L. Tong, S. Parks et al. 2012. Time-dependent changes of protein biomarker levels in the cerebrospinal fluid after blast traumatic brain injury. Electrophoresis. 33:3705-3711.
4. Ajao, D.O., V. Pop, J.E. Kamper, A. Adami, E. Rudobeck, L. Huang et al. 2012. Traumatic brain injury in young rats leads to progressive behavioral deficits coincident with altered tissue properties in adulthood. J Neurotrauma. 29:2060-2074.
5. Albert, J.M., J.P. Ioannidis, P. Reichelderfer, B. Conway, R.W. Coombs, L. Crane et al. 1998. Statistical issues for HIV surrogate endpoints: Point/counterpoint. An NIAID workshop. Statis Med. 17:2435-2462.
6. Anderson, K.J., S.W. Scheff, K.M. Miller, K.N. Roberts, L.K. Gilmer, C. Yang et al. 2008. The phosphorylated axonal form of the neurofilament subunit NF-H (pNF-H) as a blood biomarker of traumatic brain injury. J Neurotrauma. 25:1079-1085.
7. Atkinson, A.J., W.A. Colburn, V.G. DeGruttola, D.L. DeMets, G.J. Downing, D.F. Hoth et al. 2001. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Therapeutics. 69:89-95.
8. Baydas, G., V.S. Nedzvetskii, M. Tuzcu, A. Yasar, and S.V. Kirichenko. 2003. Increase of glial fibrillary acidic protein and S-100B in hippocampus and cortex of diabetic rats: Effects of vitamin E. Eur J Pharmacol. 462:67-71.
9. Bazarian, J.J., F.P. Zemlan, S. Mookerjee, and T. Stigbrand. 2006. Serum S-100B and cleaved-tau are poor predictors of long-term outcome after mild traumatic brain injury. Brain Inj. 20:759-765.
10. Bell, M.J., P.M. Kochanek, L.A. Doughty, J.A. Carcillo, P.D. Adelson, R.S. Clark et al. 1997. Interleukin-6 and interleukin-10 in cerebrospinal fluid after severe traumatic brain injury in children. J Neurotrauma. 14:451-457.
11. Berger, R.P., R.L. Hayes, R. Richichi, S.R. Beers, and K.K. Wang. 2012. Serum concentrations of ubiquitin C-terminal hydrolase-L1 and alphaII-spectrin breakdown product 145 kDa correlate with outcome after pediatric TBI. J Neurotrauma. 29:162-167.
12. Bermpohl, D., Z. You, E.H. Lo, H.H. Kim, and M.J. Whalen. 2007. TNF alpha and Fas mediate tissue damage and functional outcome after traumatic brain injury in mice. Journal of cerebral blood flow and metabolism: Official journal of the International Society of Cerebral Blood Flow and Metabolism. 27:1806-1818.
13. Bettermann, K., and J.E. Slocomb. 2012. Chapter 1: Clinical relevance of biomarkers for traumatic brain injury. In: D. Thurston (ed.), Biomarkers for Traumatic Brain Injury. The Royal Society of Chemistry, Cambridge, UK. 1-18.
14. Biomarkers Definitions Working Group. 2001. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Therapeutics. 69:89-95.
15. Birnie, M., R. Morrison, R. Camara, and K.I. Strauss. 2013. Temporal changes of cytochrome P450 (Cyp) and eicosanoid-related gene expression in the rat brain after traumatic brain injury. BMC Genom. 14:303.
16. Blyth, B.J., A. Farahvar, H. He, A. Nayak, C. Yang, G. Shaw, and J.J. Bazarian. 2011. Elevated serum ubiquitin carboxy-terminal hydrolase L1 is associated with abnormal blood-brain barrier function after traumatic brain injury. J Neurotrauma. 28:2453-2462.
17. Bock, J.L., A.J. Singer, and H.C. Thode, Jr. 2008. Comparison of emergency department patient classification by point-of-care and central laboratory methods for cardiac troponin I. American journal of clinical pathology. 130:132-135.
18. Bohmer, A.E., J.P. Oses, A.P. Schmidt, C.S. Peron, C.L. Krebs, P.P. Oppitz et al. 2011. Neuron-specific enolase, S100B, and glial fibrillary acidic protein levels as outcome predictors in patients with severe traumatic brain injury. Neurosurgery. 68:1624-1630; discussion 1630-1621.
19. Boone, C.W., and G.J. Kelloff. 1993. Intraepithelial neoplasia, surrogate endpoint biomarkers, and cancer chemoprevention. J Cell Biochem Suppl. 17F:37-48.
20. Bossuyt, P.M., J.B. Reitsma, D.E. Bruns, C.A. Gatsonis, P.P. Glasziou, L.M. Irwig et al. 2003. The STARD statement for reporting studies of diagnostic accuracy: Explanation and elaboration. Clin Chem. 49:7.
21. Bouzat, P., G. Francony, P. Declety, C. Genty, A. Kaddour, P. Bessou et al. 2011. Transcranial Doppler to screen on admission patients with mild to moderate traumatic brain injury. Neurosurgery. 68:1603-1609; discussion 1609-1610.
22. Bressan, S., M. Daverio, F. Martinolli, D. Dona, F. Mario, I.P. Steiner, and L.D. Dalt. 2014. The use of handheld near-infrared device (Infrascanner) for detecting intracranial haemorrhages in children with minor head injury. Child’s nervous system: ChNS: Official journal of the International Society for Pediatric Neurosurgery. 30:477-484.
23. Brodie, B. 1828. Pathological and surgical observations relating to injuries of the brain: Part I. Med Chir Trans. 14:325-423.
24. Brophy, G.M., S. Mondello, L. Papa, S.A. Robicsek, A. Gabrielli, J. Tepas, 3rd et al. 2011. Biokinetic analysis of ubiquitin C-terminal hydrolase-L1 (UCH-L1) in severe traumatic brain injury patient biofluids. J Neurotrauma. 28:861-870.
25. Brophy, G.M., J.A. Pineda, L. Papa, S.B. Lewis, A.B. Valadka, H.J. Hannay et al. 2009. alphaII-Spectrin breakdown product cerebrospinal fluid exposure metrics suggest differences in cellular injury mechanisms after severe traumatic brain injury. J Neurotrauma. 26:471-479.
26. Brotman, B., and A.M. Prince. 1988. Gamma-glutamyltransferase as a potential surrogate marker for detection of the non-A, non-B carrier state. Vox Sanguinis. 54:144-147.
27. Bucher, H.C., G.H. Guyatt, D.J. Cook, A. Holbrook, and F.A. McAlister. 1999. Users’ guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article Measuring the effect of an intervention on surrogate endpoints. Evidence-Based Medicine Working Group. JAMA. 282:771-778.
28. Caeyenberghs, K., A. Leemans, I. Leunissen, K. Michiels, and S.P. Swinnen. 2013. Topological correlations of structural and functional networks in patients with traumatic brain injury. Front Hum Neurosci. 7:726.
29. Cardali, S., and R. Maugeri. 2006. Detection of alphaII-spectrin and breakdown products in humans after severe traumatic brain injury. J Neurosurg Sci. 50:25-31.
30. Chen, X.H., V.E. Johnson, K. Uryu, J.Q. Trojanowski, and D.H. Smith. 2009. A lack of amyloid beta plaques despite persistent accumulation of amyloid beta in axons of long-term survivors of traumatic brain injury. Brain Pathol. 19:214-223.
31. Cheng, S.X., S. Zhang, H.T. Sun, and Y. Tu. 2013. Effects of mild hypothermia treatment on rat hippocampal beta-amyloid expression following traumatic brain injury. Therapeutic Hypotherm Temp Manage. 3:132-139.
32. Chobanian, A.V. 1983. The influence of hypertension and other hemodynamic factors in atherogenesis. Progr Cardiovasc Dis. 26:177-196.
33. Chuang-Stein, C., and R. DeMasi. 1998. Surrogate endpoints in AIDS drug development: Current status. Drug Information J. 32:439-448.
34. Clark, R.S., P.M. Kochanek, P.D. Adelson, M.J. Bell, J.A. Carcillo, M. Chen, S.R et al. 2000. Increases in bcl-2 protein in cerebrospinal fluid and evidence for programmed cell death in infants and children after severe traumatic brain injury. J Pediatr. 137:197-204.
35. Committee on Biological Markers of the National Research Council. 1987. Biological markers in environmental health research. Environ Health Perspect. 74:3-9.
36. De Gruttola, V.G., P. Clax, D.L. DeMets, G.J. Downing, S.S. Ellenberg, L. Friedman et al. 2001. Considerations in the evaluation of surrogate endpoints in clinical trials. Summary of a National Institutes of Health workshop. Control Clin trials. 22:485-502.
37. Diaz-Arrastia, R., K.K. Wang, L. Papa, M.D. Sorani, J.K. Yue, A.M. Puccio et al. 2014. Acute biomarkers of traumatic brain injury: Relationship between plasma levels of ubiquitin C-terminal hydrolase-L1 and glial fibrillary acidic protein. J Neurotrauma. 31:19-25.
38. Donaldson, M., J. Sullivan, and A. Norbeck. 2010. Comparison of International Normalized Ratios provided by two point-of-care devices and laboratory-based venipuncture in a pharmacist-managed anticoagulation clinic. American journal of health-system pharmacy: AJHP: Official journal of the American Society of Health-System Pharmacists. 67:1616-1622.
39. Donato, R. 2001. S100: A multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol. 33:637-668.
40. Eapen, D.J., P. Manocha, N. Ghasemzedah, R.S. Patel, H. Al Kassem, M. Hammadah, E. Veledar, N.A. Le, T. Pielak, C.W. Thorball, A. Velegraki, D.T. Kremastinos, S. Lerakis, L. Sperling, and A.A. Quyyumi. 2014. Soluble urokinase plasminogen activator receptor level is an independent predictor of the presence and severity of coronary artery disease and of future adverse events. Journal of the American Heart Association. 3:e001118.
41. Egea-Guerrero, J., F. Murillo-Cabezas, E. Gordillo-Escobar, A. Rodríguez-Rodríguez, J. Enamorado-Enamorado, J. Revuelto-Rey et al, 2013a. S100B protein may detect brain death development after severe traumatic brain injury. J Neurotrauma. 30:1762-1769.
42. Egea-Guerrero, J.J., J. Revuelto-Rey, E. Gordillo-Escobar, A. Rodriguez-Rodriguez, J. Enamorado-Enamorado, Z. Ruiz de Azua Lopez et al, 2013b. Serologic behavior of S100B protein in patients who are brain dead: Preliminary results. Transplant Proc. 45:3569-3572.
43. Everson, R.G., R.M. Jin, X. Wang, M. Safaee, R. Scharnweber, D.N. Lisiero, H. Soto, L.M. Liau, and R.M. Prins. 2014. Cytokine responsiveness of CD8(+) T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients. Journal for immunotherapy of cancer. 2:10.
44. Fang, X., B.M. Balgley, and C.S. Lee. 2009. Recent advances in capillary electrophoresis-based proteomic techniques for biomarker discovery. Electrophoresis. 30:3998-4007.
45. Faul, M., L. Xu, M. Wald, and V. Coronado. 2010. Traumatic Brain Injury in the United States: Emergency Department Visits, Hospitalizations and Deaths 2002-2006. Atlanta (GA): Centers for Disease Control and Prevention, National Center for Injury Prevention and Control.
46. Finkelstein, E., P. Corso, and T. Miller. 2006. The Incidence and Economic Burden of Injuries in the United States. Oxford University Press, New York.
47. Fleischer, A.S., D.R. Rudman, C.B. Fresh, and G.T. Tindall. 1977. Concentration of 3',5' cyclic adenosine monophosphate in ventricular CSF of patients following severe head trauma. J Neurosurg. 47:517-524.
48. Fonteh, A.N., R.J. Harrington, A.F. Huhmer, R.G. Biringer, J.N. Riggins, and M.G. Harrington. 2006. Identification of disease markers in human cerebrospinal fluid using lipidomic and proteomic methods. Dis Markers. 22:39-64.
49. Food and Drug Administration (FDA). 2014. Medical Device User Fee and Modernization Act (MDUFMA).
50. Fox, W.C., M.S. Park, S. Belverud, A. Klugh, D. Rivet, and J.M. Tomlin. 2013. Contemporary imaging of mild TBI: The journey toward diffusion tensor imaging to assess neuronal damage. Neurol Res. 35:223-232.
51. Fozouni, N., M. Chopp, S.P. Nejad-Davarani, Z.G. Zhang, N.L. Lehman, S. Gu et al. 2013. Characterizing brain structures and remodeling after TBI based on information content, diffusion entropy. PLoS One. 8:e76343.
52. Gabbita, S.P., S.W. Scheff, R.M. Menard, K. Roberts, I. Fugaccia, and F.P. Zemlan. 2005. Cleaved-tau: A biomarker of neuronal damage after traumatic brain injury. J Neurotrauma. 22:83-94.
53. Garnett, M., T. Cadoux-Hudson, and P. Styles. 2001. How useful is magnetic resonance imaging in predicting severity and outcome in traumatic brain injury? Curr Opin Neurol. 14:753-757.
54. Gatson, J.W., V. Warren, K. Abdelfattah, S. Wolf, L.S. Hynan, C. Moore et al. 2013. Detection of beta-amyloid oligomers as a predictor of neurological outcome after brain injury. J Neurosurg. 118:1336-1342.
55. Glenn, T.C., D. Hirt, G. Mendez, D.L. McArthur, R. Sturtevant, S. Wolahan et al. 2013. Metabolomic analysis of cerebral spinal fluid from patients with severe brain injury. Acta Neurochir Suppl. 118:115-119.
56. Goncalves, C.A., M.C. Leite, and P. Nardin. 2008. Biological and methodological features of the measurement of S100B, a putative marker of brain injury. Clin Biochem. 41:755-763.
57. Greenberg, R.B. 1976. Medical Device Amendments of 1976. Am J Hosp Pharmacy. 33:1308-1311.
58. Guingab-Cagmat, J.D., E.B. Cagmat, F.H. Kobeissy, and J. Anagli. 2014. Uses and challenges of bioinformatic tools in mass spectrometric-based proteomic brain perturbation studies. International journal of bioinformatics research and applications. 10:27-42.
59. Guingab-Cagmat, J.D., K. Newsom, A. Vakulenko, E.B. Cagmat, F.H. Kobeissy, S. Zoltewicz et al. 2012. In vitro MS-based proteomic analysis and absolute quantification of neuronal-glial injury biomarkers in cell culture system. Electrophoresis. 33:3786-3797.
60. Gura, M., G. Silav, N. Isik, and I. Elmaci. 2012. Noninvasive estimation of cerebral perfusion pressure with transcranial Doppler ultrasonography in traumatic brain injury. Turkish Neurosurg. 22:411-415.
61. Haines, I.E., and G.L. Gabor Miklos. 2013. Prostate-specific antigen screening trials and prostate cancer deaths: The androgen deprivation connection. Journal of the National Cancer Institute. 105:1534-1539.
62. Harris, J.L., H.W. Yeh, I.Y. Choi, P. Lee, N.E. Berman, R.H. Swerdlow, S.C. Craciunas, and W.M. Brooks. 2012. Altered neurochemical profile after traumatic brain injury: (1)H-MRS biomarkers of pathological mechanisms. Journal of cerebral blood flow and metabolism: Official journal of the International Society of Cerebral Blood Flow and Metabolism. 32:2122-2134.
63. Haselwood, B.A., and J.T. La Belle. 2014. Development of electrochemical methods to enzymatically detect traumatic brain injury biomarkers. Biosensors & bioelectronics. Sep 17, p. ii: S0956-5663(14)00719-2. doi: 10.1016/j.bios.2014.09.032.
64. He, W., L.S. Wang, H.Z. Li, L.G. Cheng, M. Zhang, and C.G. Wladyka. 2013. Intraoperative contrast-enhanced ultrasound in traumatic brain surgery. ClinI Imaging. 37:983-988.
65. Herrmann, M., P. Vos, M.T. Wunderlich, C.H. de Bruijn, and K.J. Lamers. 2000. Release of glial tissue-specific proteins after acute stroke: A comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein. Stroke. 31:2670-2677.
66. Huber, B.R., J.S. Meabon, T.J. Martin, P.D. Mourad, R. Bennett, B.C. Kraemer et al. 2013. Blast exposure causes early and persistent aberrant phospho- and cleaved-tau expression in a murine model of mild blast-induced traumatic brain injury. JAD. 37:309-323.
67. Hulscher, J.B., B.H. Vervliet, N. Wilczak, and J. van der Naalt. 2014. The diagnostic value of brain-fatty acid binding protein in traumatic brain injury. J Neurotrauma. 31:411.
68. Izumi, K., W.J. Lin, H. Miyamoto, C.K. Huang, A. Maolake, Y. Kitagawa, Y. Kadono, H. Konaka, A. Mizokami, and M. Namiki. 2014. Outcomes and predictive factors of prostate cancer patients with extremely high prostate-specific antigen level. Journal of cancer research and clinical oncology. 140:1413-1419.
69. Jonsson, H., P. Johnsson, P. Hoglund, C. Alling, and S. Blomquist. 2000. Elimination of S100B and renal function after cardiac surgery. J Cardiothor Vasc Anesth. 14:698-701.
70. Kiebish, M.A., X. Han, H. Cheng, J.H. Chuang, and T.N. Seyfried. 2008. Cardiolipin and electron transport chain abnormalities in mouse brain tumor mitochondria: Lipidomic evidence supporting the Warburg theory of cancer. J Lipid Res. 49:2545-2556.
71. Kleindienst, A., and M. Ross Bullock. 2006. A critical analysis of the role of the neurotrophic protein S100B in acute brain injury. J Neurotrauma. 23:1185-1200.
72. Kobeissy, F.H., S. Sadasivan, M.W. Oli, G. Robinson, S.F. Larner, Z. Zhang et al. 2008. Neuroproteomics and systems biology-based discovery of protein biomarkers for traumatic brain injury and clinical validation. Proteomics Clin Appl. 2:1467-1483.
73. Koizumi, H., H. Fujisawa, T. Kurokawa, E. Suehiro, H. Iwanaga, J. Nakagawara et al. 2010. Recovered neuronal viability revealed by Iodine-123-iomazenil SPECT following traumatic brain injury. J Cereb Blood Flow Metab. 30:1673-1681.
74. Koizumi, H., H. Fujisawa, E. Suehiro, H. Iwanaga, J. Nakagawara, and M. Suzuki. 2013. Cortical damage following traumatic brain injury evaluated by iomazenil SPECT and in vivo microdialysis. Acta Neurochir Suppl. 118:121-123.
75. Kovesdi, E., J. Luckl, P. Bukovics, O. Farkas, J. Pal, E. Czeiter et al. 2010. Update on protein biomarkers in traumatic brain injury with emphasis on clinical use in adults and pediatrics. Acta Neurochir (Wien). 152:1-17.
76. Laser, H., T.G. Mack, D. Wagner, and M.P. Coleman. 2003. Proteasome inhibition arrests neurite outgrowth and causes “dying-back” degeneration in primary culture. J Neurosci Res. 74:906-916.
77. Lesko, L., and A.J. Atkinson. 2001. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: Criteria, validation, strategies. Annu Rev Pharmacol Toxicol. 41:347-366.
78. Ligthart, S., S. Sedaghat, M.A. Ikram, A. Hofman, O.H. Franco, and A. Dehghan. 2014. EN-RAGE: A Novel Inflammatory Marker for Incident Coronary Heart Disease. Arteriosclerosis, thrombosis, and vascular biology. Oct. 23, p. ii: ATVBAHA.114.304306.
79. Lonn, E. 2001. The use of surrogate endpoints in clinical trials: Focus on clinical trials in cardiovascular diseases. Pharmacoepidem Drug Safe. 10:497-508.
80. Loov, C., G. Shevchenko, A. Geeyarpuram Nadadhur, F. Clausen, L. Hillered, M. Wetterhall et al. 2013. Identification of injury specific proteins in a cell culture model of traumatic brain injury. PLoS One. 8:e55983.
81. Marklund, N., N. Farrokhnia, A. Hanell, E. Vanmechelen, P. Enblad, H. Zetterberg et al. 2014. Monitoring of beta-amyloid dynamics after human traumatic brain injury. J Neurotrauma. 31:42-55.
82. May, G. 1850. Illustrations of the tolerance of injuries occasionally exhibited by the brain. Prov Med Surg J. 14:8-10.
83. McClain, C., D. Cohen, R. Phillips, L. Ott, and B. Young. 1991. Increased plasma and ventricular fluid interleukin-6 levels in patients with head injury. J Lab Clin Med. 118:225-231.
84. McClain, C.J., D. Cohen, L. Ott, C.A. Dinarello, and B. Young. 1987. Ventricular fluid interleukin-1 activity in patients with head injury. J Lab Clin Med. 110:48-54.
85. Mendez, M.F., E.M. Owens, G. Reza Berenji, D.C. Peppers, L.J. Liang, and E.A. Licht. 2013. Mild traumatic brain injury from primary blast vs. blunt forces: Post-concussion consequences and functional neuroimaging. NeuroRehabilitation. 32:397-407.
86. Missler, U., M. Wiesmann, G. Wittmann, O. Magerkurth, and H. Hagenstrom. 1999. Measurement of glial fibrillary acidic protein in human blood: Analytical method and preliminary clinical results. Clin Chem. 45:138-141.
87. Molloy, M.P., E.E. Brzezinski, J. Hang, M.T. McDowell, and R.A. VanBogelen. 2003. Overcoming technical variation and biological variation in quantitative proteomics. Proteomics. 3:1912-1919.
88. Mondello, S., A. Linnet, A. Buki, S. Robicsek, A. Gabrielli, J. Tepas et al. 2012. Clinical utility of serum levels of ubiquitin C-terminal hydrolase as a biomarker for severe traumatic brain injury. Neurosurgery. 70:666-675.
89. Mondello, S., S.A. Robicsek, A. Gabrielli, G.M. Brophy, L. Papa, J. Tepas et al. 2010. alphaII-spectrin breakdown products (SBDPs): Diagnosis and outcome in severe traumatic brain injury patients. J Neurotrauma. 27:1203-1213.
90. Mynter, H. 1894 III. Contribution to the Study of head injuries, and of the results of trephining for subdural haemorrhage, abscess of brain, and epilepsy. Ann Surg. 19:539-545.
91. Nanduri, S., A.H. Tayal, G.G. Hegde, J. Shang, and A. Venkat. 2012. An analysis of discrepancy between point-of-care and central laboratory international normalized ratio testing in ED patients with cerebrovascular disease. The American journal of emergency medicine. 30:2025-2029.
92. Newberg, A.B., M. Serruya, A. Gepty, C. Intenzo, T. Lewis, D. Amen et al. 2014. Clinical comparison of (99m)Tc exametazime and (123)I ioflupane SPECT in patients with chronic mild traumatic brain injury. PLoS One. 9:e87009.
93. Nissen, S.E., E.M. Tuzcu, P. Schoenhagen, B.G. Brown, P. Ganz, R.A. Vogel, T. Crowe, G. Howard, C.J. Cooper, B. Brodie, C.L. Grines, and A.N. DeMaria. 2004. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. Jama. 291:1071-1080.
94. Nylen, K., M. Ost, L.Z. Csajbok, I. Nilsson, K. Blennow, B. Nellgard et al. 2006. Increased serum-GFAP in patients with severe traumatic brain injury is related to outcome. J Neurol Sci. 240:85-91.
95. Obuchowski, N.A., M.L. Lieber, and F.H.W. Jr. 2004. ROC curves in clinical chemistry: Uses, misuses, and possible solutions. Clin Chem. 50:1118.
96. Okegawa, T., N. Itaya, H. Hara, M. Tambo, and K. Nutahara. 2014. Circulating Tumor Cells as a Biomarker Predictive of Sensitivity to Docetaxel Chemotherapy in Patients with Castration-resistant Prostate Cancer. Anticancer research. 34:6705-6710.
97. Okonkwo, D.O., J.K. Yue, A.M. Puccio, D.M. Panczykowski, T. Inoue, P.J. McMahon et al. 2013. GFAP-BDP as an acute diagnostic marker in traumatic brain injury: Results from the prospective transforming research and clinical knowledge in traumatic brain injury study. J Neurotrauma. 30:1490-1497.
98. Ondruschka, B., D. Pohlers, G. Sommer, K. Schober, D. Teupser, H. Franke et al. 2013. S100B and NSE as useful postmortem biochemical markers of traumatic brain injury in autopsy cases. J Neurotrauma. 30:1862-1871.
99. Ottens, A.K., F.H. Kobeissy, B.F. Fuller, M. Chen Liu, M.W. Oli, R.L. Hayes et al. 2007. Novel neuroproteomic approaches to studying traumatic brain injury. Prog Brain Res. 161:401-418.
100. Ottens, A.K., F.H. Kobeissy, E.C. Golden, Z. Zhang, W.E. Haskins, S.S. Chen et al. 2006. Neuroproteomics in neurotrauma. Mass Spectrom Rev. 25:380-408.
101. Paone, J.F., T.P. Waalkes, R.R. Baker, and J.H. Shaper. 1980. Serum UDP-galactosyl transferase as a potential biomarker for breast carcinoma. J Surg Oncol. 15:59-66.
102. Papa, L., L. Akinyi, M.C. Liu, J.A. Pineda, J.J. Tepas, 3rd, M.W. Oli et al. 2010. Ubiquitin C-terminal hydrolase is a novel biomarker in humans for severe traumatic brain injury. Crit Care Med. 38:138-144.
103. Papa, L., L.M. Lewis, S. Silvestri, J.L. Falk, P. Giordano, G.M. Brophy et al. 2012. Serum levels of ubiquitin C-terminal hydrolase distinguish mild traumatic brain injury from trauma controls and are elevated in mild and moderate traumatic brain injury patients with intracranial lesions and neurosurgical intervention. J Trauma Acute Care Surg. 72:1335-1344.
104. Pataky, R., R. Gulati, R. Etzioni, P. Black, K.N. Chi, A.J. Coldman, T. Pickles, S. Tyldesley, and S. Peacock. 2014. Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada. International journal of cancer. Journal international du cancer. 135:939-947.
105. Peck, C.C., D.B. Rubin, and L.B. Sheiner. 2003. Hypothesis: A single clinical trial plus causal evidence of effectiveness is sufficient for drug approval. Clin Pharmacol Therapeutics. 73:481-490.
106. Pineda, J.A., S.B. Lewis, A.B. Valadka, L. Papa, H.J. Hannay, S.C. Heaton et al. 2007. Clinical significance of alphaII-spectrin breakdown products in cerebrospinal fluid after severe traumatic brain injury. J Neurotrauma. 24:354-366.
107. Prentice, R.L. 1989. Surrogate endpoints in clinical trials: Definition and operational criteria. Stat Med. 8:431-440.
108. Riederer, B.M., I.S. Zagon, and S.R. Goodman. 1986. Brain spectrin(240/235) and brain spectrin(240/235E): Two distinct spectrin subtypes with different locations within mammalian neural cells. J Cell Biol. 102:2088-2097.
109. Robertson, C.L., N. Minamino, R.A. Ruppel, K. Kangawa, S.R. Wisniewski, T. Tsuji et al. 2001. Increased adrenomedullin in cerebrospinal fluid after traumatic brain injury in infants and children. J Neurotrauma. 18:861-868.
110. Rolan, P. 1997. The contribution of clinical pharmacology surrogates and models to drug development-A critical appraisal. Br J Clin Pharmacol. 44:219-225.
111. Romner, B. 2000. Traumatic brain damage: Serum S-100 protein measurements related to neuroradiological findings. J Neurotrauma. 17:641- 647.
112. Ross, S.A., R.T. Cunningham, C.F. Johnston, and B.J. Rowlands. 1996. Neuron-specific enolase as an aid to outcome prediction in head injury. Br J Neurosurg. 10:471-476.
113. Rostami, E., J. Davidsson, K.C. Ng, J. Lu, A. Gyorgy, J. Walker et al. 2012. A model for mild traumatic brain injury that induces limited transient memory impairment and increased levels of axon related serum biomarkers. Front Neurol. 3:115.
114. Rudman, D., A. Fleischer, and M.H. Kutner. 1976. Concentration of 3', 5' cyclic adenosine monophosphate in ventricular cerebrospinal fluid of patients with prolonged coma after head trauma or intracranial hemorrhage. N Engl J Med. 295:635-638.
115. Sarkar, K., K. Keachie, U. Nguyen, J.P. Muizelaar, M. Zwienenberg-Lee, and K. Shahlaie. 2014. Computed tomography characteristics in pediatric versus adult traumatic brain injury. J Neurosurg Pediatr. 13;307-314.
116. Sarubbo, S., F. Latini, S. Ceruti, A. Chieregato, C. d’Esterre, T.Y. Lee et al. 2014. Temporal changes in CT perfusion values before and after cranioplasty in patients without symptoms related to external decompression: A pilot study. Neuroradiology. 56: 237-243.
117. Satchell, M.A., Y. Lai, P.M. Kochanek, S.R. Wisniewski, E.L. Fink, N.A. Siedberg et al. 2005. Cytochrome c, a biomarker of apoptosis, is increased in cerebrospinal fluid from infants with inflicted brain injury from child abuse. J Cereb Blood Flow Metab. 25:919-927.
118. Selakovic, V., R. Raicevic, and L. Radenovic. 2005. The increase of neuron-specific enolase in cerebrospinal fluid and plasma as a marker of neuronal damage in patients with acute brain infarction. J Clin Neurosci. 12:542-547.
119. Selwyn, R., N. Hockenbury, S. Jaiswal, S. Mathur, R.C. Armstrong, and K.R. Byrnes. 2013. Mild traumatic brain injury results in depressed cerebral glucose uptake: An (18)FDG PET study. J Neurotrauma. 30:1943-1953.
120. Sharifi, K., Y. Morihiro, M. Maekawa, Y. Yasumoto, H. Hoshi, Y. Adachi et al. 2011. FABP7 expression in normal and stab-injured brain cortex and its role in astrocyte proliferation. Histochem Cell Biol. 136:501-513.
121. Shirinian, E. 1971a. Catecholamine metabolism in guinea pig tissues in craniocerebral injuries. Biull Eksp Biol Med., 71:46-49.
122. Shirinian, E. 1971b. The effect of craniocerebral trauma on catecholamine metabolism in the heart, liver and adrenals of guinea pigs. Vopr Med Khim., 17:640-644.
123. Shultz, S., L. Cardamone, Y. Liu, R. Hogan, L. Maccotta, D. Wright et al. 2013. Can structural or functional changes following traumatic brain injury in the rat predict epileptic outcome? Epilepsia. 54:1240-1250.
124. Siman, R., N. Giovannone, G. Hanten, E.A. Wilde, S.R. McCauley, J.V. Hunter et al. 2013. Evidence that the blood biomarker SNTF predicts brain imaging changes and persistent cognitive dysfunction in mild TBI patients. Front Neurol. 4:190.
125. Strathmann, F.G., S. Schulte, K. Goerl, and D.J. Petron. 2014. Blood-based biomarkers for traumatic brain injury: Evaluation of research approaches, available methods and potential utility from the clinician and clinical laboratory perspectives. Clin Biochem. 47:876-888.
126. Strimbu, K., and J. Tavel. 2010. What are biomarkers? Curr Opin HIV AIDS. 5:463-466.
127. Su, E., M.J. Bell, P.M. Kochanek, S.R. Wisniewski, H. Bayir, R.S. Clark et al. 2012. Increased CSF concentrations of myelin basic protein after TBI in infants and children: Absence of significant effect of therapeutic hypothermia. Neurocrit Care. 17:401-407.
128. Tajiri, N., S.L. Kellogg, T. Shimizu, G.W. Arendash, and C.V. Borlongan. 2013. Traumatic brain injury precipitates cognitive impairment and extracellular Abeta aggregation in Alzheimer’s disease transgenic mice. PLoS One. 8:e78851.
129. Takayanagi, Y., G. Gerner, M. Takayanagi, V. Rao, T.D. Vannorsdall, A. Sawa et al. 2013. Hippocampal volume reduction correlates with apathy in traumatic brain injury, but not schizophrenia. J Neuropsychiatry Clin Neurosci. 25:292-301.
130. Taurines, R., E. Dudley, J. Grassl, A. Warnke, M. Gerlach, A.N. Coogan, and J. Thome. 2011. Proteomic research in psychiatry. J Psychopharmacol. 25:151-196.
131. Temple, R. 1995. A regulatory authority’s opinion about surrogate endpoints. In: Nimmo, W.S. and G.T. Tucker (eds.), Clinical Measurement in Drug Evaluation, Wiley, New York.
132. Thelin, E.P., L. Johannesson, D. Nelson, and B.M. Bellander, 2013a. S100B is an important outcome predictor in traumatic brain injury. J Neurotrauma. 30:519-528.
133. Thelin, E.P., D.W. Nelson, and B.M. Bellander, 2013b. Secondary peaks of S100B in serum relate to subsequent radiological pathology in traumatic brain injury. Neurocrit Care. 20:217-219.
134. Toyama, Y., T. Kobayashi, Y. Nishiyama, K. Satoh, M. Ohkawa, and K. Seki. 2005. CT for acute stage of closed head injury. Radiat Medi. 23:309-316.
135. Vajtr, D., O. Benada, P. Linzer, F. Samal, D. Springer, P. Strejc et al. 2012. Immunohistochemistry and serum values of S-100B, glial fibrillary acidic protein, and hyperphosphorylated neurofilaments in brain injuries. Soud Lek. 57:7-12.
136. Valiyaveettil, M., Y.A. Alamneh, Y. Wang, P. Arun, S. Oguntayo, Y. Wei et al. 2014. Cytoskeletal protein alpha-II spectrin degradation in the brain of repeated blast exposed mice. Brain Res. 1549:32-41.
137. Viant, M.R., B.G. Lyeth, M.G. Miller, and R.F. Berman. 2005. An NMR metabolomic investigation of early metabolic disturbances following traumatic brain injury in a mammalian model. NMR Biomed. 18:507-516.
138. Vos, P.E., K.J. Lamers, J.C. Hendriks, M. van Haaren, T. Beems, C. Zimmerman et al. 2004. Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury. Neurology. 62:1303-1310.
139. Walsh, B.H., D.I. Broadhurst, R. Mandal, D.S. Wishart, G.B. Boylan, L.C. Kenny et al. 2012. The metabolomic profile of umbilical cord blood in neonatal hypoxic ischaemic encephalopathy. PLoS One. 7:e50520.
140. Wang, C., X. Fang, and C.S. Lee, 2013a. Recent advances in capillary electrophoresis-based proteomic techniques for biomarker discovery. Methods Mol Biol. 984:1-12.
141. Wang, Y.Q., L. Wang, M.Y. Zhang, T. Wang, H.J. Bao, W.L. Liu, D.K. Dai, L. Zhang, P. Chang, W.W. Dong, X.P. Chen, and L.Y. Tao. 2012. Necrostatin-1 suppresses autophagy and apoptosis in mice traumatic brain injury model. Neurochemical research. 37:1849-1858.
142. Wang, Y., Y. Wang, M. Li, P. Xu, T. Gu, T. Ma et al, 2013b. (1)H NMR-based metabolomics exploring biomarkers in rat cerebrospinal fluid after cerebral ischemia/reperfusion. Mole bioSys. 9:431-439.
143. Weir, C.J., and R.J. Walley. 2006. Statistical evaluation of biomarkers as surrogate endpoints: A literature review. Stat Medi. 25:183-203.
144. Whalen, M.J., T.M. Carlos, P.M. Kochanek, S.R. Wisniewski, M.J. Bell, R.S. Clark et al. 2000. Interleukin-8 is increased in cerebrospinal fluid of children with severe head injury. Crit Care Med. 28:929-934.
145. White, T.E., G.D. Ford, M.C. Surles-Zeigler, A.S. Gates, M.C. Laplaca, and B.D. Ford. 2013. Gene expression patterns following unilateral traumatic brain injury reveals a local pro-inflammatory and remote anti-inflammatory response. BMC Genom. 14:282.
146. WHO. 1993. Biomarkers and Risk Assessment: Concepts and Principles, from http://apps.who.int/iris/handle/10665/39037.
147. WHO. 2001. Biomarkers in Risk Assessment: Validity and Validation, from http://apps.who.int/iris/handle/10665/42363.
148. Wolf, H., S. Frantal, G.S. Pajenda, O. Salameh, H. Widhalm, S. Hajdu et al. 2013. Predictive value of neuromarkers supported by a set of clinical criteria in patients with mild traumatic brain injury: S100B protein and neuron-specific enolase on trial: Clinical article. J Neurosurg. 118:1298-1303.
149. Wu, P., Y. Zhao, S.J. Haidacher, E. Wang, M.O. Parsley, J. Gao et al. 2013. Detection of structural and metabolic changes in traumatically injured hippocampus by quantitative differential proteomics. J Neurotrauma. 30:775-788.
150. Yuan, X., and D.M. Desiderio. 2005. Proteomics analysis of prefractionated human lumbar cerebrospinal fluid. Proteomics. 5:541-550.
151. Zurek, J., L. Bartlova, and M. Fedora. 2011. Hyperphosphorylated neurofilament NF-H as a predictor of mortality after brain injury in children. Brain Inj. 25:221-226.
152. Zurek, J., and M. Fedora. 2012. The usefulness of S100B, NSE, GFAP, NF-H, secretagogin and Hsp70 as a predictive biomarker of outcome in children with traumatic brain injury. Acta Neurochir (Wien). 154:93-103; discussion 103.